{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:38:10Z","timestamp":1794465490408,"version":"4.9.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017357","name":"Science and Technology Projects of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDA0580000"],"award-info":[{"award-number":["XDA0580000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J01999"],"award-info":[{"award-number":["2024J01999"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J0111191"],"award-info":[{"award-number":["2023J0111191"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110616","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:13:00Z","timestamp":1791501180000},"page":"110616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer"],"prefix":"10.1016","volume":"183","author":[{"given":"Jianping","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.bioorg.2026.110616_bb0005","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-positive early breast Cancer: primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110616_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106934","article-title":"Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis","volume":"196","author":"Sevieri","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110616_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116032","article-title":"Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors","volume":"264","author":"Zhou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0020","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ijc.34024","article-title":"The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction","volume":"151","author":"Bouwer","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"29","key":"10.1016\/j.bioorg.2026.110616_bb0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026849118","article-title":"Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance","volume":"118","author":"Upton","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2026.110616_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107687","article-title":"Leveraging HER2-targeted biparatopic antibodies in solid tumors","volume":"214","author":"Liu","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110616_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030971","article-title":"Advances in radionuclides and radiolabelled peptides for cancer therapeutics","volume":"15","author":"Chakraborty","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110616_bb0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110616_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116919","article-title":"(211)At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma","volume":"279","author":"Ye","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110616_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2025.344754","article-title":"Innovative design of CXCR4 cyclic peptide via molecular docking for (99m)Tc-labeled SPECT\/CT imaging in melanoma","volume":"1381","author":"Yin","year":"2026","journal-title":"Anal. Chim. Acta"},{"issue":"21","key":"10.1016\/j.bioorg.2026.110616_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216482","article-title":"Review: radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides","volume":"26","author":"Ge","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110616_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092409","article-title":"Radionuclide therapy of HER2-expressing xenografts using [(177)Lu]Lu-ABY-027 affibody molecule alone and in combination with trastuzumab","volume":"15","author":"Liu","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0065","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.30500","article-title":"Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients","volume":"140","author":"Bhusari","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110616_bb0070","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","article-title":"[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models","volume":"51","author":"Zeng","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110616_bb0075","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1021\/acsmedchemlett.5c00472","article-title":"Synthesis and evaluation of [177Lu]Lu-labeled-NLS-Trastuzumab conjugate for targeting of HER2 positive metastatic breast cancer: evaluating the effect on intracellular localization","volume":"16","author":"Kolay","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0080","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2967\/jnumed.122.264816","article-title":"Cure of disseminated human lymphoma with [(177)Lu]Lu-ofatumumab in a preclinical model","volume":"64","author":"Shim","year":"2023","journal-title":"J. Nucl. Med.: Off. Publ. Soc. Nucl. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110616_bb0085","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10967-021-08174-0","article-title":"In vitro and in vivo evaluation of a novel anti-EGFR antibody labeled with 89Zr and 177Lu","volume":"331","author":"Liu","year":"2022","journal-title":"J. Radioanal. Nucl. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11307-023-01846-1","article-title":"Intricacies in the preparation of patient doses of [177Lu]Lu-rituximab and [177Lu]Lu-trastuzumab using low specific activity [177Lu]LuCl3: methodological aspects","volume":"26","author":"Chakraborty","year":"2024","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.bioorg.2026.110616_bb0095","article-title":"Astatine-211 based radionuclide therapy: current clinical trial landscape","volume":"9","author":"Albertsson","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/med.70008","article-title":"Astatine-211-towards in vivo stable Astatine-211 labeled radiopharmaceuticals and their (pre)clinical applications","volume":"46","author":"M\u00fcller","year":"2026","journal-title":"Med. Res. Rev."},{"issue":"S33","key":"10.1016\/j.bioorg.2026.110616_bb0105","article-title":"SSP-30-225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy \u2013 an in vitro and in vivo evaluation","volume":"96-97","author":"Rodak","year":"2021","journal-title":"Nucl. Med. Biol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110616_bb0110","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.125.269601","article-title":"(225)Ac \u03b1-pretargeted radioimmunotherapy of human epidermal growth factor receptor 2-expressing breast cancer","volume":"66","author":"Rinne","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110616_bb0115","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.0c00580","article-title":"Therapeutic efficacy of (213)Bi-labeled sdAbs in a preclinical model of ovarian cancer","volume":"17","author":"Dekempeneer","year":"2020","journal-title":"Mol. Pharm."},{"issue":"40","key":"10.1016\/j.bioorg.2026.110616_bb0120","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.3748\/wjg.v30.i40.4367","article-title":"Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer","volume":"30","author":"Kong","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2026.110616_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1647218","article-title":"Case report: effectiveness of Inetetamab combined with immunochemotherapy as first-line treatment in two cases of advanced gastric cancer with HER2 expression: a retrospective analysis","volume":"15","author":"Wu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110616_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2023.103597","article-title":"Exploring the clinical outcomes and safety profile of Inetetamab treatment in metastatic breast cancer patients: a multicenter assessment of a Chinese-origin recombinant anti-HER2 monoclonal antibody","volume":"72","author":"Liu","year":"2023","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cpt.2023.10.004","article-title":"Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: a single-arm phase 2 clinical trial","volume":"2","author":"Jin","year":"2024","journal-title":"Cancer Pathog. Ther."},{"key":"10.1016\/j.bioorg.2026.110616_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108000","article-title":"From molecular engineering to clinical applications: the expanding role of bispecific antibodies in onco-immunology","volume":"221","author":"Borrelli","year":"2025","journal-title":"Pharmacol. Res."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110616_bb0145","doi-asserted-by":"crossref","first-page":"22034","DOI":"10.18632\/oncotarget.15787","article-title":"Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer","volume":"8","author":"Maisonial-Besset","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13550-020-00685-3","article-title":"177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma","volume":"10","author":"Delage","year":"2020","journal-title":"EJNMMI Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0155","article-title":"Systemic investigation of Inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers","volume":"18","author":"Deng","year":"2023","journal-title":"Open Life Sci."},{"issue":"D1","key":"10.1016\/j.bioorg.2026.110616_bb0160","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110616_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1218670","article-title":"Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry","volume":"11","author":"George","year":"2023","journal-title":"Front. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110616_bb0170","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1039\/D1SC06182H","article-title":"Template directed synthesis of antibody fc conjugates with concomitant ligand release","volume":"13","author":"Postupalenko","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2026.110616_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109240","article-title":"Recent advances in radionuclide drug conjugates (RDCs) for cancer theranostics: from targeted design to clinical translation","volume":"167","author":"Xijing","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12951-020-00610-9","article-title":"Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules","volume":"18","author":"Ho","year":"2020","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41523-022-00430-0","article-title":"Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials","volume":"8","author":"Chumsri","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010212","article-title":"FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0200","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202403075","article-title":"Crosstalk between TGF-\u03b2 and EGF receptors via direct phosphorylation","volume":"223","author":"Moustakas","year":"2024","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0205","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202307138","article-title":"HER2 phosphorylation induced by TGF-\u03b2 promotes mammary morphogenesis and breast cancer progression","volume":"223","author":"Shi","year":"2024","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110616_bb0190","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundl\u00f6v","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0210","first-page":"71","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110616_bb0215","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1535-7163.MCT-21-1021","article-title":"Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HER2pos Cancer","volume":"21","author":"Rodak","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110616_bb0220","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-025-00337-8","article-title":"In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with (225)Ac","volume":"10","author":"Ondr\u00e1k Fialov\u00e1","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0225","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acs.molpharmaceut.7b00985","article-title":"Evaluation of an anti-HER2 nanobody labeled with (225)Ac for targeted \u03b1-particle therapy of cancer","volume":"15","author":"Pruszynski","year":"2018","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110616_bb0230","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/1078-0432.CCR-24-1779","article-title":"Complete remissions of HER2-positive trastuzumab-resistant xenografts using a potent [225Ac]Ac-labeled anti-HER2 antibody-drug radioconjugate","volume":"31","author":"Pougoue Ketchemen","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110616_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102009","article-title":"Glucose metabolism modification induced by radioligand therapy with [(177)Lu]Lu\/[(90)Y]Y-DOTATOC in advanced neuroendocrine neoplasms: a prospective pilot study within FENET-2016 trial","volume":"14","author":"Urso","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110616_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000635","article-title":"223-radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy","volume":"5","author":"Anderson","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110616_bb0245","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1007\/s00259-023-06316-y","article-title":"Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics","volume":"50","author":"M\u00fcller","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110616_bb0250","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2967\/jnumed.122.265268","article-title":"(161)Tb-DOTATOC production using a fully automated disposable cassette system: a first step toward the introduction of (161)Tb into the clinic","volume":"64","author":"Favaretto","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110616_bb0255","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1007\/s12274-024-6974-x","article-title":"A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"Nano Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110616_bb0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","article-title":"Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives","volume":"21","author":"Marra","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110616_bb0265","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1039\/D0SC00062K","article-title":"Fast surface immobilization of native proteins through catalyst-free amino-yne click bioconjugation","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:25:17Z","timestamp":1794461117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":53,"alternative-id":["S0045206826011521"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110616","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110616"}}